Beam Therapeutics is laying off 100 employees and rejigging its pipeline priorities to save cash, citing a “challenging market environment.”
The new project hierarchy, disclosed Thursday, will focus on the two lead programs, BEAM-101 and ESCAPE, both aimed at treating patients with sickle cell disease, with the latter also being developed to treat beta thalassemia. Alongside these, Beam will prioritize BEAM-302, which is currently in IND-enabling studies for the treatment of alpha-1 antitrypsin deficiency.
The biotech’s cost savings are coming primarily from layoffs and sunsetting work on its base-edited CAR-Ts. The company said it will look to accrue a “focused clinical dataset” on phase 1-stage BEAM-201 and seek partnerships for that asset and other ex vivo CAR-T programs. An update to the clinical trial record last month included two additional trial sites, in California and Colorado, respectively. An AAV program for Stargardt disease has also been removed from Beam’s public pipeline.
Roughly 100 employees are being laid off, the company said, equating to 20% of the entire workforce. The exits are expected to be completed before the end of the year and will cost the company about $6.6 million in severance-related charges.
All told, the moves extend the company’s cash runway into 2026. Beam had about $1.1 billion in cash and investment securities as of June 30, with a third-quarter earnings date yet to be announced. Such is life in biotech these days, where having more than $1 billion at your disposal still doesn’t insulate you from the perils of a frigid market.
Stymying Beam’s momentum has been BEAM-101’s phase 1/2 trial, which has yet to dose a single patient. CEO John Evans told Fierce Biotech in August that it was still “plausible” that the company would see the first dose administered before the end of the year. A previously enrolled patient dropped out earlier this year for personal reasons, which Evans said knocked the company back.
It takes about six months for Beam to prepare a patient for dosing, and there’s a 40-day buffer period between dosing subsequent patients to make sure engraftment occurs. Evans affirmed in August that the biotech expects data on multiple patients next year. The first patient has now been dosed in a phase 1/2 trial for BEAM-201, a study that began almost a year after the BEAM-101 trial launched, according to an announcement last month.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...